カテゴリ： GlobalData, アメリカ, 企業調査

Catabasis Pharmaceuticals Inc (CATB)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Catabasis Pharmaceuticals Inc (CATB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C7963
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：64
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Catabasis Pharmaceuticals Inc (Catabasis Pharmaceuticals) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes medicines for the treatment of multiple diseases. The company develops its product candidates using its proprietary safely metabolized and rationally targeted (SMART) Linker drug discovery platform for rare diseases, among others. Its product candidate edasalonexent CAT-1004, currently under Phase 3 trial, is an oral small molecule intended for the treatment of Duchenne muscular dystrophy. CAT-5571, an activator of autophagy and the company’s lead product under preclinical stage, is an oral small molecule for the treatment of cystic fibrosis. The company’s CAT-4001 is used for the treatment of neurodegenerative diseases such as Friedreich’s ataxia and amyotrophic lateral sclerosis (ALS). Catabasis Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.

Catabasis Pharmaceuticals Inc (CATB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Catabasis Pharma Raises USD12.41 Million in Venture Financing 11
Catabasis Pharma Raises US$32.4 Million In Series B Financing 12
Partnerships 14
Catabasis Pharma Enters into Agreement with Sarepta Therapeutics 14
Catabasis Pharma Enters into Co-Development Agreement with Muscular Dystrophy Association 15
Catabasis Pharma Enters into Agreement with Actigraph 16
Equity Offering 17
Catabasis Pharma Raises USD42 Million in IPO of Shares 17
Catabasis Pharma Plans to Raise up to USD10 Million in Public Offering of Shares 18
Catabasis Pharma Raises USD4.3 Million in Public Offering of Shares 19
Catabasis Pharma Raises USD11.5 Million in Public Offering of Shares 20
Catabasis Pharma Raises USD69 Million in IPO 22
Catabasis Pharmaceuticals Inc – Key Competitors 23
Catabasis Pharmaceuticals Inc – Key Employees 24
Catabasis Pharmaceuticals Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Financial Announcements 26
Aug 09, 2018: Catabasis Pharmaceuticals reports second quarter 2018 financial results and reviews business progress 26
May 10, 2018: Catabasis Pharmaceuticals Reports First Quarter 2018 Financial Results and Reviews Business Progress 28
Mar 15, 2018: Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Reviews Business Progress 29
Nov 09, 2017: Catabasis Pharmaceuticals Reports Third Quarter 2017 Financial Results 31
Aug 10, 2017: Catabasis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Reviews Business Progress 33
May 11, 2017: Catabasis Pharmaceuticals Reports First Quarter 2017 Financial Results and Reviews Business Progress 35
Mar 16, 2017: Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Highlights 37
Corporate Communications 39
Feb 17, 2017: Catabasis Pharmaceuticals Announces Promotion of Ted Hibben to Chief Business Officer 39
Product News 40
09/28/2017: Catabasis Pharmaceuticals to Present Results from Joint Research Collaboration with Sarepta Therapeutics at the 22nd International Congress of the World Muscle Society 40
04/25/2017: Catabasis Pharmaceuticals Announces Favorable Results for Functional Assessments in the MoveDMD Trial for Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting 41
01/31/2017: Catabasis Pharmaceuticals Announces Top-Line Results for Part B of the MoveDMD Trial for Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy 43
Clinical Trials 45
Oct 03, 2018: Catabasis Pharmaceuticals presents data supporting MRI T2 as a potential marker of clinical outcome in duchenne muscular dystrophy at the World Muscle Society Congress 45
Sep 27, 2018: Catabasis Pharmaceuticals begins Phase lll DMD trial of edasalonexent 47
Sep 19, 2018: Catabasis Pharmaceuticals to present new Edasalonexent clinical results and phase 3 trial design in duchenne muscular dystrophy at the World Muscle Society Congress 48
Jul 09, 2018: Catabasis to initiate POLARIS DMD trial of edasalonexent 49
Jun 25, 2018: Catabasis Pharmaceuticals Presents New Edasalonexent Clinical Biomarker Data Showing NF-kB Inhibition and Target Engagement in the MoveDMD Trial 50
Jun 18, 2018: Catabasis Pharmaceuticals to Present at Upcoming Scientific and Advocacy Conferences 51
Apr 25, 2018: Catabasis Pharmaceuticals Presents New Edasalonexent Data Showing Significantly Slowed Duchenne Muscular Dystrophy Disease Progression As Measured By MRI Through One Year Of Treatment 52
Apr 18, 2018: Catabasis Pharmaceuticals to Present Results from the MoveDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 70th Annual Meeting 54
Apr 17, 2018: Catabasis Pharmaceuticals Aligns Resources to Focus on Lead Program Edasalonexent for the Treatment of Duchenne Muscular Dystrophy 55
Feb 13, 2018: Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of Treatment 56
Oct 04, 2017: Catabasis Pharmaceuticals Reports Positive Results From Open-Label Extension Of Phase 2 MoveDMD Trial Evaluating Edasalonexent In Duchenne Muscular Dystrophy And Plans To Initiate Phase 3 Clinical Trial In First Half 2018 58
Sep 14, 2017: Catabasis Pharmaceuticals to Present Results from the Open-Label Extension of the MoveDMD Phase 2 Trial of Edasalonexent in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society 60
Jun 23, 2017: Catabasis Pharmaceuticals to Present Results from the MoveDMD Trial of Edasalonexent at the 2017 PPMD Annual Connect Conference 61
Jan 19, 2017: Catabasis Pharmaceuticals Phase 1 Data on Edasalonexent (CAT-1004), a Potential Disease-Modifying Therapy Being Developed for Duchenne Muscular Dystrophy, Published in the Journal of Clinical Pharmacology 62
Jan 04, 2017: Positive Preclinical Research on the Edasalonexent (CAT-1004) Program, a Potential Disease-Modifying Therapy for Duchenne Muscular Dystrophy, Published in JCI Insight 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64

List of Tables
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Catabasis Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Catabasis Pharma Raises USD12.41 Million in Venture Financing 11
Catabasis Pharma Raises US$32.4 Million In Series B Financing 12
Catabasis Pharma Enters into Agreement with Sarepta Therapeutics 14
Catabasis Pharma Enters into Co-Development Agreement with Muscular Dystrophy Association 15
Catabasis Pharma Enters into Agreement with Actigraph 16
Catabasis Pharma Raises USD42 Million in IPO of Shares 17
Catabasis Pharma Plans to Raise up to USD10 Million in Public Offering of Shares 18
Catabasis Pharma Raises USD4.3 Million in Public Offering of Shares 19
Catabasis Pharma Raises USD11.5 Million in Public Offering of Shares 20
Catabasis Pharma Raises USD69 Million in IPO 22
Catabasis Pharmaceuticals Inc, Key Competitors 23
Catabasis Pharmaceuticals Inc, Key Employees 24

List of Figures
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Catabasis Pharmaceuticals Inc (CATB)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Kukje Pharmaceutical Industry Co Ltd (002720)：企業の財務・戦略的SWOT分析
    Summary Kukje Pharmaceutical Industry Co Ltd (Kukje) is a manufacturer, and distributor of pharmaceuticals, cosmetics and healthcare products. The company’s products include cephalosporins, penicillins, quinolones, aminoglycosides, macrolides, other antibiotics, antifungal and antiviral agents. Kukj …
  • Penumbra Inc (PEN)：企業の財務・戦略的SWOT分析
    Penumbra Inc (PEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Westmoreland Coal Company：企業の戦略・SWOT・財務情報
    Westmoreland Coal Company - Strategy, SWOT and Corporate Finance Report Summary Westmoreland Coal Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Inivata Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Inivata Ltd (Inivata) is a cancer genomics company. The company offers products such as invisionfirst- lungin and visionseq. Its InVisionFirst offers advanced sequencing technology to detect single nucleotide variants copy number variants, insertions and deletions and structural variants in …
  • WB Electronics SA ：企業の戦略・SWOT・財務情報
    WB Electronics SA - Strategy, SWOT and Corporate Finance Report Summary WB Electronics SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • The Royal Bank Of Scotland Group Plc：企業の戦略・SWOT・財務分析
    The Royal Bank Of Scotland Group Plc - Strategy, SWOT and Corporate Finance Report Summary The Royal Bank Of Scotland Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Verseon Corp (VSN)：企業の財務・戦略的SWOT分析
    Summary Verseon Corp (Verseon) is a pharmaceutical company that develops novel therapeutics. The company develops drug programs in the therapeutic areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology. Its anticoagulation program develops oral anticoagulants for cardi …
  • Insightra Medical Inc-医療機器分野：企業M&A・提携分析
    Summary Insightra Medical Inc (Insightra Medical), a subsidiary of GPB Life Science Holdings LLC is a medical device company that develops disposable devices. The company offers cardiovascular and surgical solutions. Its cardiovascular solutions include Ultra 7FR IAB and modulare. The Modulare Cathe …
  • Bank Of The Philippine Islands：企業の戦略・SWOT・財務分析
    Bank Of The Philippine Islands - Strategy, SWOT and Corporate Finance Report Summary Bank Of The Philippine Islands - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Celldex Therapeutics, Inc.：企業の戦略・SWOT・財務分析
    Celldex Therapeutics, Inc. - Strategy, SWOT and Corporate Finance Report Summary Celldex Therapeutics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Shanghai Pharmaceutical Co Ltd (601607)：製薬・医療：M&Aディール及び事業提携情報
    Summary Shanghai Pharmaceutical Co Ltd (Shanghai Pharma) is a manufacturer, retailer, wholesaler and distributor of healthcare products. The company carries out the research and development, manufacture and sale of pharmaceutical products for treating HER2 positive advanced breast cancer, systemic a …
  • Lockheed Martin Aeronautics Company
    Lockheed Martin Aeronautics Company - Strategy, SWOT and Corporate Finance Report Summary Lockheed Martin Aeronautics Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Immunovia AB (IMMNOV)：企業の財務・戦略的SWOT分析
    Summary Immunovia AB (Immunovia) is a molecular diagnostics company that offers clinical testing for early diagnosis of pancreatic cancer. The company develops IMMray, a technology platform based on antibody microarray analysis, which can be used in the early diagnosis of cancer, predicting disease …
  • Fenchem Inc：企業の戦略・SWOT・財務分析
    Fenchem Inc - Strategy, SWOT and Corporate Finance Report Summary Fenchem Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Zuivelcooperatie FrieslandCampina UA：企業の戦略的SWOT分析
    Zuivelcooperatie FrieslandCampina UA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Petro Welt Technologies AG (O2C)：企業の財務・戦略的SWOT分析
    Petro Welt Technologies AG (O2C) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • curasan AG (CUR)：医療機器：M&Aディール及び事業提携情報
    Summary curasan AG (curasan) develops, manufactures and commercializes medical devices in the field of regenerative medicine. The company offers a wide range of synthetic bone substitutes, dental and bone regeneration material products. It offers these products to orthopedic and spinal surgeons, ora …
  • Vital Therapies Inc (VTL)：医療機器：M&Aディール及び事業提携情報
    Summary Vital Therapies Inc (Vital Therapies) is a biotechnology company that discovers, develops and commercialize cell-based therapies. The company’s product candidate includes ELAD system, a human-cell-based bio artificial liver treatment designed to allow the patient's own liver to regenerate or …
  • The Save Mart Companies：戦略・SWOT・企業財務分析
    The Save Mart Companies - Strategy, SWOT and Corporate Finance Report Summary The Save Mart Companies - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Charles River Laboratories International Inc (CRL)：製薬・医療：M&Aディール及び事業提携情報
    Summary Charles River Laboratories International Inc (Charles River) is a contract research organization (CRO) that provides essential products and services to accelerate the research, drug discovery and development. It offers various basic research, drug discovery and safety assessment services. Th …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆